Shiga toxin-producing Escherichia coli (STEC) are a group of food-borne pathogens 74 causing acute and bloody diarrhea, which may progress to life-threatening complications 75 such as hemolytic uremic syndrome (HUS). 1 To date there is no specific treatment for 76 STEC infection and antibiotic use is contraindicated due to increased risk of HUS 77 development. 2 While STEC O157:H7 is the serotype most frequently associated with 78 diarrhea outbreaks and HUS cases worldwide, there are other serotypes, the incidence 79 and impact of which on public health and the food industry have increased. 3,4 80 STEC colonizes the human colon and produces Shiga toxins (Stx) that can enter the 81 blood stream and disseminate to organs such as the kidneys and central nervous 82 system. Once Stx reach the target organs and enter the cells, the toxins inhibit protein 83 synthesis, leading to autophagy and apoptosis and ultimately tissue damage, which may 84 lead to HUS. 5 85
To colonize the human colon, STEC requires several virulence factors like those 86 encoded in the locus of enterocyte effacement (LEE) pathogenicity island (PAI). LEE-87 mediated adherence causes the formation of the "attaching and effacing" lesion and loss 88 of microvilli of the intestinal epithelial cells. 6 In addition, STEC strains lacking LEE (LEE-89 negative STEC) harbor other PAIs like the Locus of Adhesion and Autoaggregation 90 (LAA), which encodes virulence factors involved in intestinal colonization. 7, 8 In fact, the 91 presence of two or more PAIs in single isolates of clinically relevant STEC serotypes is 92 common, suggesting that the cumulative acquisition of mobile genetic elements 93 encoding virulence factors may contribute additively or synergistically to pathogenicity. 8,9 94 Vaccination of the infant population, which is the highest-risk group for STEC infections, 95 and animal reservoirs have been proposed as a preventive approach that could reduce 96 their incidence and prevalence. However, there is no approved STEC vaccine for 97 humans, and commercial vaccines used in cattle reduce but do not eliminate colonization 98 and shedding of these bacteria. 10 Therefore, the development of an effective STEC 99 vaccine is still underway. STEC proteins involved in attachment to host tissues are 100 eligible targets for vaccine development, as they determine initial steps during infection; 101 however, the selection of antigens that may provide a broadly and protective immune 102 response among their diverse adhesion and colonization mechanisms is a pivotal point 103 to consider. 11 An additional difficulty for the development of an effective STEC vaccine 104 has been the lack of an animal model of infection that can reproduce the pathologies 105 caused in humans. 12 Despite these limitations, several STEC vaccine candidates have 106 been evaluated in laboratory animals (mice, rats and rabbits) and in cattle, with promising
Results 143
The OmpT, Cah and Hes proteins have several linear B-cell epitopes that are 144 recognized by IgG and IgA from HUS sera but not from control sera. 145 146 An overview of our vaccine development approach is shown in Figure 1 . We carried out 147 a high-throughput screening of linear B-cell epitopes in the OmpT, Cah and Hes proteins 148 by using a peptide microarray assay (see Methods). A total of 6, 6 and 5 epitope-like 149 spot patterns were identified in the peptide slides of OmpT, Cah and Hes proteins ( Fig.  150 2a-2c), respectively. As a complementary approach, we used a number of 151 immunoinformatics tools and found that 13 out of 17 of the experimentally identified B-152 cell epitopes were predicted in silico by one or more algorithms ( Table 1) . This result 153 highlights the advances in the accuracy of these bioinformatics tools. On the other hand, 154 it is known that MHC class II (MHC-II) epitopes included in peptide vaccines enhance T-155 cell-dependent antibody responses 28 . Thus, we also performed an in silico analysis for 156 the prediction of MHC-II binding peptides and found two putative T-cell epitopes in the 157
OmpT and Cah proteins ( Table 2) . 158 159 Because the peptide microarray assay was performed with a mix of three HUS sera, we 160 sought to confirm the reactivity of these epitopes using a larger number of sera. We also 161 tested the reactivity of the epitopes against three sera obtained from children with no 162 medical record of STEC-related disease (hereinafter referred to as control sera). For this, 163 short peptides ranging from 15 to 24 amino acids (aa) which include each epitope were 164 chemically synthesized, and their reactivity to IgG and IgA was assessed by ELISA. In 165 general, the peptides were recognized at higher levels by IgG than by IgA from HUS sera 166 ( Fig. 2d-i) . Furthermore, the peptides derived from the same antigen were recognized 167 by similar levels of IgG or IgA, with the exception of Cah_5 and Hes_5, which showed a 168 higher level of reactivity to IgG compared to Cah_4 and Hes_4, respectively ( Fig. 2f and  169 2h). The frequency of reactivity of the peptides to IgG ranged from 60% (Hes_4) to 100% 170 (Cah_5, Cah_6 and Hes_5), while for IgA it was between 29% (Cah_2) and 100% 171 (Hes_5) ( Table 1) . As expected, a polyclonal antibody response was observed within 172 individuals, evidenced by the variable concentration of IgG and IgA antibodies that 173 recognize each tested peptide ( Fig. 2j-k) . Importantly, none of the peptides was 174 recognized by IgG or IgA from control sera ( Table 1, Fig. 2j-k) . Taken together, these 175 results indicate that the identified linear B-cell epitopes are broadly recognized and 176 immunodominant during immune responses against STEC.
Chimeric proteins displaying linear B-cell epitopes of OmpT, Cah and Hes proteins 178
are recognized by IgG and IgA from HUS sera but not from control sera. 179
180
We consider that the best epitopes for vaccine development are those that are 181 conserved, broadly distributed among clinical isolates, with higher levels of reactivity and 182 surface exposition in the native antigen. Consequently, the Hes_4 (lower reactivity and 183 detection frequency) and OmpT_5 (limited surface exposition) epitopes were discarded 184 and not used in further assays. For the in silico design of proteins we implemented two 185 different approaches. Firstly, we noticed that the linear B-cell epitopes of OmpT and Hes 186 are overlapped or consecutively arranged along the protein ( Fig. 2a and 2c ), suggesting 187 that they form antigenic domains (AD). We took advantage of this and designed a 188 chimeric protein containing these AD through the fusion of 135 AA and 127 AA from 189
OmpT and Hes proteins, respectively ( Fig. 3a) . We named this protein Chimera 1 (Chi1; 190 262 AA and 29 kDa), which includes a total of eight B-cell epitopes (OmpT_1, OmpT_2, 191
OmpT_3, OmpT_4, Hes_1, Hes_2, Hes_3 and Hes_5) and two predicted T-cell epitopes 192 (Table 2 ). In the second approach, we used the passenger domain of Cah (αCah) as a 193 carrier (keeping its epitopes) and incorporated several B-cell epitopes of OmpT and Hes 194 ( Table 2, Fig. 3d ). Thus, this second protein named Chimera 2 (Chi2; 559 AA and 56 195 kDa) includes a total of eleven B-cell epitopes (OmpT_1, OmpT_6, Hes_1, Hes_2 and 196
Hes_5, Cah_1, Cah_2, Cah_3, Cah_4, Cah_5, Cah_6) and two predicted T-cell epitopes 197 (Table 2) . We next evaluated whether immune responses elicited by vaccination with the chimeric 257 antigens may confer protection against intestinal colonization by STEC. For this, two 258 weeks after the last booster immunization, mice were treated with streptomycin and then 259 orally challenged with STEC O157:H7 str. 86-24 ( Fig. 1d ; see Methods). Notably, mice 260 immunized with Chi1 plus Chi2 by intramuscular route showed a significantly lower fecal 261 shedding of the STEC 86-24 strain from day 8 post-infection to the end of the experiment 262 (day 12) compared to the PBS control group (Fig. 5a ). In mice immunized by the 263 intranasal route, only the Chi2 group showed a slight but significant decrease in fecal 264
shedding of STEC 86-24 strain on days 7 and 8 compared to the PBS control group. 265
However, on day 9 and later, this difference was not observed (Fig. 5b) . 266
On day 12 post-infection, mice were euthanized and the level of colonization of the 267 challenge strain in the cecum was determined. Consistent with the above results, 268 recovery of the STEC 86-24 strain was significantly lower in mice immunized with Chi1 269 plus Chi2 by intramuscular route than in the PBS control group, which corresponded to 270 2.1 log of protection ( Table 3) in a previous study we showed that the Stx2d-producing E. coli O91:H21 str. V07-4-4 is 282 lethal to mice when they are orally inoculated with a dose of 10 9 CFU. 8 However, with a 283 dose lower than 10 5 CFU of the STEC V07-4-4 strain, mice develop renal pathologies 284 but survive for at least 12 days (unpublished results). Therefore, we conducted further 285 work to investigate whether immunization with the chimeric antigens confers protection against renal damage caused by the STEC V07-4-4 strain. For this, two weeks after the 287 last booster immunization, mice were treated with streptomycin and orally challenged 288 with 10 5 CFU of the STEC V07-4-4 strain. Our results showed that on days 7 and 12 289 post-infection, mice intranasally immunized with Chi1, Chi2 or Chi1 plus Chi2 had 290 creatinine levels in urine similar to uninfected mice ( Fig. 5c and 5d ). This was particularly 291 evident in mice immunized with Chi1 plus Chi2. In contrast, mice immunized by 292 intramuscular route and the PBS control group showed significantly higher levels of 293 creatinine in urine than uninfected mice. Moreover, the histopathological analysis of 294 kidney tissue obtained on day 12 post-infection showed that mice immunized by 295 intranasal route had mild or no evident tissue injuries (Fig 5e) . Conversely, mice 296 immunized by intramuscular route and the PBS control group showed moderate and 297 severe tissue injuries, respectively (Fig 5e) . Urinary clinical markers such as the number 298 of leukocytes and urobilinogen levels on day 12 post-infection also evidenced the 299 protection achieved by intranasal immunizations (Table 4 ). Together, these results 300 indicate that immunization with the chimeric antigens by intranasal route protects against Here we demonstrated that immunization of mice with chimeric antigens displaying 319 selected epitopes of OMPs confers protection against intestinal colonization and renal 320 damage caused by STEC. It is well established that a suitable vaccine must be 321 composed of different antigens to boost the immune response with a wide range of 322 protection. Thus, since the OmpT, Cah and Hes proteins are widespread among STEC 323 strains, the use of these proteins as targets could confer protection against LEE-positive 324 and LEE-negative STEC strains. To our knowledge, this is the first STEC vaccine 325 candidate that includes a virulence factor of LEE-negative STEC strains. 326
In general, subunit and protein-based vaccines have proven to be safe and to have a 327 defined and homogeneous composition between production batches. This is an 328 important advantage over other types of vaccines, which may present complex 329 manufacturing processes, with subsequent regulatory and safety issues. [34] [35] [36] In Gram-330 negative bacteria, OMPs are primary components interacting with host cells; therefore, 331 vaccines targeting these proteins may be effective by blocking key pathogenic 332 mechanisms. 11,37 However, as previously mentioned, the purification and efficient 333 production of OMPs pose a major challenge. Thus, construction of water-soluble and 334 stable chimeric antigens displaying epitopes from OMPs is an approach worth exploring. 335
Our vaccine development approach takes advantage of immunoinformatics tools and in 336 vitro assays (epitope mapping, ELISA) to predict and identify linear B-cell epitopes, 337 respectively ( Fig. 1) . Previous studies have also demonstrated the usefulness of 338 immunoinformatics tools for the development of vaccine candidates against STEC and 339 other pathogens. 22, 38 Additional work conducted to evaluate the seroreactivity of the 340 epitopes using a large set of HUS sera allowed us to select the best epitopes based on 341 their frequency and level of reactivity ( Fig. 2, Table 1 ). Another important parameter we 342 considered for the selection of epitopes was the surface exposition in the native antigen, 343 which could facilitate their recognition by immune cells. Predicted T-cell epitopes were 344 also included in the structure of chimeric proteins to enhance T-cell-dependent antibody 345 responses ( Table 2) . 346 Importantly, our results provide proof-in-principle that incorporating selected linear B-cell 347 epitopes into a carrier protein, such as aCah, may result in an increase in antigenicity 348 The immunization studies showed that the Chi1 and Chi2 antigens, administered alone 353 or in combination, induce long-lasting humoral responses (Fig 4) . However, the class of 354 antibodies generated was in general dependent on the adjuvant and the administration 355 route. This dependency was most obvious in mice immunized with Chi1 plus Chi2, which 356 elicited significantly higher levels of specific IgG and IgA antibodies in serum when 357 intramuscularly immunized than when intranasally immunized ( Fig. 4a-b) . Conversely, 358 the intranasal but not the intramuscular administration of Chi1 plus Chi2 led to the 359 production of significant levels of fecal sIgA compared to the PBS control group (Fig.  360   4d) . Table 3 ). Since intramuscular immunization with Chi1 plus Chi2 did not lead to 375 significant production of specific fecal sIgA antibodies ( Fig. 4d) , it is possible to correlate 376 the protection achieved with other classes of immunoglobulins and more likely with the 377
IgG. Other vaccine candidates that generated significant levels of specific IgG antibodies 378 in serum but not fecal sIgA antibodies have also conferred protection to mice against 379 colonization by STEC O157:H7. 47 Consequently, our results and those reported by 380 others support the idea of a pivotal role of the IgG antibodies in the defense against 381 enteropathogens. This is a major finding that will be relevant to the development of 382 vaccines against these pathogens by avoiding biases in the selection of the "best" 383 immunogens based mainly on the ability to induce sIgA antibody responses. 384
Because the challenge studies were performed only to day 12 post-inoculation, it was 385 not possible to determine whether the immune responses triggered by the intramuscular 386 immunization with Chi1 and Chi2 may lead to complete clearance of STEC O157:H7.
Long-term protection experiments in mice and other animal models will complement the 388 evaluation of this vaccine candidate. 389
An effective STEC vaccine may also confer protection against the action of the Stx. 390 STEC export the Shiga toxins along with a number of OMPs and cytoplasmic proteins 391 via outer membrane vesicles (OMVs). 48-50 These OMVs may be endocytosed in a 392 dynamin-dependent manner by intestinal epithelial cells, and then OMV-associated 393 virulence factors are differentially separated from vesicles during intracellular trafficking. 394 50,51 Recently, it was reported that in the case of Stx2 but not Stx1, once the toxin is 395 internalized, it can be released from eukaryote cells in microvesicles that have exosome 396 markers. 52 Therefore, immunity against Stx may be mediated by neutralizing Stx-specific 397 antibodies or by immune mechanisms that prevent the toxin from entering the eukaryotic 398
cell. 399
Our chimeric antigens did not display Stx-associated epitopes. Consequently, the 400 protection conferred by intranasal immunizations against renal damage caused by STEC 401 O91:H21 ( Fig. 5c-e , Table 4 ) could be explained by two different mechanisms. The first 402 one, which is the simplest explanation, is that the generated immune response 403 decreased the intestinal colonization of the STEC O91:H21 strain, which could be 404 correlated with a lower release and amount of OMVs and Stx. However, in the challenge 405 experiments with the STEC O157:H7 strain, only intramuscular immunization with Chi1 406 plus Chi2 was able to confer protection against intestinal colonization ( Fig. 5a and 5b) . 407
In addition, because the levels of intestinal colonization of the STEC O91:H21 strain 408 were not measured, we cannot conclude that in our experiments a decrease in 409 colonization correlates with protection against renal damage. The second possible 410 explanation, although a bit more complex, is that sIgA antibodies generated by intranasal 411 immunizations could prevent the release and/or the endocytosis of OMVs via immune 412 exclusion. The latter explanation is supported by the fact that OmpT and Ag43 (a Cah 413 homologue protein) are transported in OMVs. 51, 53 In fact, it has been reported that OmpT 414 regulates the biogenesis of OMVs. 54 415
In some vaccines, it has been shown that the combination of administration routes, for 416 example mucosal priming followed by systemic boosting or systemic priming followed by 417 mucosal boosting, leads to robust humoral and cellular responses that improve their 418 efficacy. 55, 56 In future studies we will investigate whether the combination of systematic 419 and mucosal immunizations with the Chi1 and Chi2 antigens leads to a more robust and 420 complete immune response characterized by the production of both systemic and 421 secretory antibodies. Also, we will endeavor to reveal the mechanism by which intranasal 422 immunization with Chi1 and Chi2 confers protection against renal damage caused by 423 STEC O91:H21. 424
In conclusion, we developed a promising STEC vaccine candidate that confers protection 425 against intestinal colonization and renal damage. Our results strongly support the 426 potential use of this vaccine as a preventive strategy against STEC infections. . Peptides binding to MHC-II molecules were also predicted on the IEDB server 57 . 479 480
Validation of epitopes by ELISA assay 481
Seventeen short peptides from 15 to 24 amino acids ( Table 1) Predicted three-dimensional structure of Chimera 1 was constructed based on the crystal 509 structures of the Opa60 (PDB_ID: 2MLH) 61 and OmpT (PDB_ID: 1I78) 62 proteins. The 510 template for Chimera 2 structure was the crystal structure of the Ag43 protein (PDB_ID: 511 4KH3). 63 Comparative modeling of chimeric proteins was performed in Modeller v9 512 software 64 , using default parameters. The modeled structures were solvated and 513 embedded in a water box using ions (Na+, Cl-) to neutralize the system with the TCL 514 script using VMD software. 65 The models were optimized with cycles of energy 515 minimization and dynamics using the NAMD 2.12 software. 66 A molecular dynamics 516 simulation was performed under periodic bordering conditions and isobaric-isothermal 517 set (NPT). The entire system was relaxed by molecular dynamics (MD) simulations using 518 NAMD 2.12 software for 10 ns and subsequently balanced for 30 ns, using the force field 519 CHARMM v2.7. 67 Quality evaluation and validation of the models were carried out by 520 USA), respectively (Fig. 1d) . Experimental groups 1, 3 and 5 were i.m. immunized with 556 either 20 μg of Chi1, 20 μg of Chi2 or 10 μg of Chi1 plus 10 μg of Chi2, respectively. 557
Experimental groups 2, 4 and 6 were i.n. immunized with either 20 μg of Chi1, 20 μg of 558
Chi2 or 10 μg of Chi1 plus 10 μg of Chi2, respectively. The control group were injected 559 with PBS plus adjuvants. Two booster immunizations were performed on days 15 and 560 30 using similar amounts of protein formulations and adjuvants. 561 562
Sera and feces collection 563
Sera were obtained from five mice per group by tail vein bleeding on days -2, 14 and 28 564 before each immunization and at day 42 (two weeks after the last booster immunization), 565 according to conventional techniques. Briefly, blood samples were left at 37 °C for 30 566 min and then centrifuged at 1,000 x g for 10 min. Supernatant was collected, the 567 complement was inactivated at 56 °C for 30 min and aliquots were stored at -80 °C until 568
IgG, IgA and IgM determinations by ELISA. For secretory IgA (sIgA) measurement, feces 569 were collected on days -2, 14, 28 and 42. Feces were weight, homogenized and diluted 570 to 0.1 g/ml with PBS containing 0.1% sodium azide and 1 mM of phenylmethylsulfonyl 571 fluoride (PMSF). Fecal suspension was centrifuged at 15,000 x g for 5 min at 4 °C, the 572 supernatant fluid recovered and again centrifuged at 15,000 x g for 15 min at 4 °C and 573 stored at -80 °C until use. 574 575
Measurement of humoral response 576
Chimeric proteins were diluted to 1 µg/ml in carbonate buffer (pH 9.6) and used to coat 577 polystyrene 96-well high-binding ELISA plates (100 µl/well; Nunc-Immuno plate with 578
MaxiSorp surface). After overnight incubation at 4 °C, plates were washed with washing 579 buffer (Tris-buffered saline [pH 7.4] with 0.05% Tween 20) and blocked with 0.8% gelatin 580 in TPBS for 1 h at 37 °C and then incubated with either sera or supernatant from fecal 581 suspensions, at a dilution of 1:100, for 2.5 h at room temperature and washed four times. 582
Next, isotype-specific goat anti-mouse HRP conjugates (BioLegend, USA) were added 583 (100 µl/well) at a dilution of 1:1000 and incubated for 1 h min at room temperature 584 followed by washing with TPBS. Then, 200 µl/well of OPD Peroxidase Substrate (Cat. 585 P9187-5SET, Sigma-Aldric, USA) was added for 30 min. The reaction was stopped with 586 50 µl/well of 2N H2SO4 and the absorbance at 450 nm was measured on a microplate 587 reader. 588
589
Challenge studies 590
Two weeks after the last booster immunization (day 45), the infection experiments were 591 performed in the streptomycin-treated mouse model of STEC infection as described 592 elsewhere 72,73 with minor modifications. Briefly, mice were given water ad libitum 593 containing streptomycin (5 g/l) 24-48 h prior to inoculation and for the duration of the 594 experiment. Feces were documented to be free of streptomycin-resistant E. coli at the 595 time of inoculation. STEC O157:H7 86-24 and STEC O91:H21 V07-4-4 strains were grown overnight in agitated LB broth containing 50 µg/ml streptomycin at 37 °C. Cultures 597 were centrifuged, washed once with PBS and resuspended in a 20% sucrose (w/v) and 598 10% NaHCO3 (w/v) solution in sterile water to 1 x 10 10 CFU/ml (STEC 86-24 strain) or 1 599
x 10 6 CFU/ml (STEC V07-4-4 strain). Prior to inoculation, mice were starved of food and 600 water overnight (12 h). The next morning mice were orally infected by pipette feeding 601 with 100 µl of bacterial suspension containing 10 9 CFU or 10 5 CFU of STEC 86-24 or 602 STEC V07-4-4 strains, respectively. After challenge, food and water were reintroduced 603 and provided ad libitum. The fecal shedding of the 86-24 strain was recorded daily for 12 604 days. For this, feces were collected, weighed, homogenized, suspended in 1 ml PBS 605 and, after serial dilutions, plated on MacConkey agar plates supplemented with 606 streptomycin (50 µg/ml) for bacterial counts. For determination of intestinal colonization 607 of the STEC 86-24 strain, 12 days after challenge (day 57), mice were euthanized, and 608 cecum was collected under aseptic conditions, homogenized and diluted in PBS. 609
Suspensions were serially diluted and plated on MacConkey supplemented with 610 streptomycin (50 µg/ml) for bacterial counts. Log10 units of protection were obtained by 611 subtracting the mean Log10 CFU for each experimental group from the mean Log10 CFU 612 of the PBS control group. Mice inoculated with the STEC V07-4-4 strain were used to 613 measure kidney damage (vide infra). 614 615
Urinalysis 616
Urine samples were collected as previously described 74 , on days 45, 51 and 57 (0, 7 617 and 12 post-infection, respectively) from mice infected with the STEC V07-4-4 strain. 618
Biochemical estimation of urine creatinine concentration was assessed using the 619
Creatinine Kit (BioSystems, Spain) according to the manufacturer's instructions. Other 620 clinical urine markers were measured by using Combur10 Test®M semiquantitative test 621 strips (Roche Diagnostics GmbH, Germany). Each test strip consists of colorimetric 622 reaction spots for 10 markers: specific gravity (1.000 to 1.030), pH (5.0 to 9.0), 623 leukocytes (range, negative to 500 cells/µL), nitrites (negative or positive), proteins 624 (negative to 500 mg/dl), glucose (negative to 55 mmol/l), ketones (negative to 15 625 mmol/L), urobilinogen (normal to 200 µmol/L), bilirubin (negative to +3) and blood 626 (negative; trace of non-hemolyzed; or hemolyzed, 10 to 250 cells/µL). Each square was 627 wet with a drop of urine and the marker value was determined through comparison with 628 a colorimetric standard. 629 630
Histopathological analysis of kidney tissue 631
For the histological analysis of kidney tissue, mice infected with the STEC V07-4-4 strain 632 were euthanized at day 57, the kidneys collected, fixed in 10% formaldehyde (pH 6.9), were analyzed by immunoinformatics tools and a peptide microarray assay for B-cell 676 epitope prediction and mapping, respectively. MHC-II epitopes were also predicted in 677 silico. Several B-cell epitopes were validated by ELISA using a collection of HUS sera. HUS sera (n=20) that are reactive to short peptides containing B-cell epitopes of the 714
OmpT, Cah and Hes proteins. A lower number of HUS sera and Hes epitopes were 715 assessed due to sera availability. Tukey box plots show the 25 th to 75 th percentiles, with 716 the median indicated by the horizontal line inside the box. Data analysis was by Kruskal-717 Wallis test, followed by Dunn's multiple comparison test. *P < 0.0 5 was considered 718 significant. j and k) Heatmaps show the logarithm of the IgG and IgA concentration of 719 each serum (HUS or control sera) that recognizes a specific short peptide, respectively. 720
Data were clustered hierarchically using Euclidean distance and complete linkage 721
analyses. Each row represents a different serum and each column a specific epitope. 722
The 778  779  780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797 Cellular injuries were classified as not evident, mild, moderate or severe as described in 814
the Methods. Cellular injuries are color coded as indicated in the legend at the top. 815
Differences between experimental groups and uninfected mice were analyzed by a two-816 way ANOVA followed by Tukey's multiple comparison test. For all statistical analyses P 817 < 0.0 5 was considered significant. 818 819 820 821 822 
Funding and acknowledgments 860
This study was supported by FONDEF ID16I10140 and FONDECYT 1161161 grants. 861
We thank Dr. Helen Lowry for the careful revision and edition of the manuscript. We 862 thank Dr. Mauricio Farfan for sharing the STEC O157:H7 str. 86-24. 863 864
Conflict of interest 865
Currently, an application for an international patent had been presented for the chimeric 866 antigens developed and uses thereof. 
